[CAS NO. 2869954-98-1] Werner syndrome RecQ helicase-IN-3
PRODUCTS SPECIFICATIONS [2869954-98-1]
DESCRIPTION [2869954-98-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 687.07 |
| Molecular Formula | C31H30ClF3N8O5 |
| SMILES | O=C(N1CCN(CC1)C2=C(CC)N(CC(NC3=CC=C(C(F)(F)F)C=C3Cl)=O)C4=NC(C5=CCOCC5)=NN4C2=O)C6=NC=CC=C6O |
Summary
Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC 50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity [1] .
IC50 & Target
IC 50 : 0.06 µM (WRN) [1]
In Vitro
Werner syndrome RecQ helicase-IN-3 (example 96) (0-10 µM; 8-20 days) shows antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
| Cell Line: | SW48, DLD1 WRN-KO cells |
| Concentration: | 0-10 µM |
| Incubation Time: | 8-20 days |
| Result: | Showed antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively. |
In Vivo
Werner syndrome RecQ helicase-IN-3 (120 mg/kg; daily for 22 days) shows anticancer activity in mouse [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells) [1] |
| Dosage: | 120 mg/kg |
| Administration: | P.o.; daily for 22 days |
| Result: | Inhibited tumor growth. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.